NASDAQ:MAPP - MAP Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc. Receive MAPP News and Ratings via Email Sign-up to receive the latest news and ratings for MAPP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:MAPP Previous Symbol CUSIPN/A CIK1401923 WebN/A Phone+1-302-6587581Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable MAP Pharmaceuticals (NASDAQ:MAPP) Frequently Asked Questions What is MAP Pharmaceuticals' stock symbol? MAP Pharmaceuticals trades on the NASDAQ under the ticker symbol "MAPP." Has MAP Pharmaceuticals been receiving favorable news coverage? Media coverage about MAPP stock has trended somewhat positive on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MAP Pharmaceuticals earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the healthcare company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. How do I buy shares of MAP Pharmaceuticals? Shares of MAPP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact MAP Pharmaceuticals? MAP Pharmaceuticals' mailing address is 2525 Dupont Dr, IRVINE, CA 92612-1531, United States. The healthcare company can be reached via phone at +1-302-6587581. MarketBeat Community Rating for MAP Pharmaceuticals (NASDAQ MAPP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 79 (Vote Outperform)Underperform Votes: 65 (Vote Underperform)Total Votes: 144MarketBeat's community ratings are surveys of what our community members think about MAP Pharmaceuticals and other stocks. Vote "Outperform" if you believe MAPP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAPP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: What Does a Sell-Side Analyst Rating Mean? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.